TD Cowen raised the firm’s price target on Ardelyx (ARDX) to $10 from $9 and keeps a Buy rating on the shares. The firm said the reported Q3 product sales of $105.5MM, above the consensus of $98.2MME. Ibsrela sales were $78.2MM versus $70.9MME consensus, and given strength, the company has again raised FY25 Ibsrela sales guidance to $270-275MM.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx’s Strong Financial Performance and Growth Potential Drive Buy Rating
- Ardelyx’s Strategic Growth and Pipeline Potential Justify Buy Rating
- Ardelyx Reports Strong Q3 Growth and Pipeline Expansion
- Ardelyx’s Strong Market Performance and Growth Potential Justify Buy Rating and Raised Price Target
- Ardelyx reports Q3 EPS 0c, consensus (7c)